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ABSTRACT 
Telemedicine allows the remote exchange of medical data between patients and healthcare 
professionals. It is used to increase patients’ access to care and provide effective healthcare services 
at a distance. During the recent COVID-19 pandemic, telemedicine has thrived and emerged 
worldwide as an indispensable resource to improve the management of isolated patients due to 
“lockdown” or “shielding”, including those with hypertension. The best proposed healthcare model 
for telemedicine in hypertension management should include remote monitoring and transmission 
of vital signs (notably blood pressure) and medication adherence plus education on lifestyle and risk 
factors, with video consultation as an option. The use of mixed automated feedback services with 
supervision of a multidisciplinary clinical team (physician, nurse or pharmacist) is the ideal 
approach. The indications include screening for suspected hypertension, management of older 
adults, medically underserved people, high-risk hypertensive patients, patients with multiple 
diseases, and those isolated due to pandemics or national emergencies. 
Keywords: telemedicine; telehealth; e-health; m-health; arterial hypertension; COVID-19 
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BACKGROUND 
Telemedicine (or telehealth) represents a revolutionary patient management approach combining 
various forms of information communication technology (ICT) in order to remotely deliver care, 
consultation, medical education, specific healthcare and clinical services, and for monitoring 
patients’ parameters at distance [1]. It is a promising tool for improving access to care, empowering 
patients, influencing their attitudes and behaviors, and ultimately enhancing their medical 
conditions. 
Telemedicine is expected to be increasingly utilized in the near future for acute and chronic 
disease management due to the ageing population with increased life expectancy and better survival 
from cardiovascular (CV) events leading to greater population health burden. The role of 
telemedicine has become increasingly clear in light of the COVID-19 pandemic. Bringing 
hypertensive patients into clinics for routine BP checks during a pandemic represents a serious risk, 
especially for older adults or those with underlying medical conditions. Social distancing and 
reduced mobility required to control the COVID-19 pandemic have highlighted and intensified the 
pressing need for telemedicine as the only way to manage a number of chronic conditions, 
including hypertension [2,3]. Furthermore, particularly in rural areas, practical issues in traveling to 
healthcare facilities make telemedicine attractive. COVID-19, combined with ongoing shortages of 
physicians and nurses, may affect access to appropriate care for an aging population with multiple 
morbidities and impaired mobility.  
Hypertension is a good target for telemedicine, and in particular, for telemonitoring, as it is the 
most common and important risk factor for CV disease worldwide [4]. However, while 
telemedicine has been shown to improve blood pressure (BP) control as compared to standard care, 
its place in daily clinical practice is not yet clear [5]. Whilst most guidelines refer to it in the context 
of excluding white coat or masked hypertension, there are no current specific recommendations on 
the place of telemedicine in general hypertension management, with the partial exception of the 
2017 American College of Cardiology (ACC) / American Heart Association (AHA) guidelines 
which suggest that telehealth strategies can be useful adjuncts to interventions shown to reduce BP 
for adults with hypertension [6]. 
SCOPE OF THE CONSENSUS POSITION PAPER 
This consensus position paper aims to critically review the available evidence on the clinical 
usefulness and application and the current barriers and challenges for telemedicine in hypertension 
management. The different technological and clinical aspects will be presented and discussed. The 
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focus will be on telemonitoring, the telemedicine solution proven to be the most effective for 
hypertension management [7]. The potential of telemedicine for maintaining continuity of care for 
hypertensive patients in the time of infectious disease outbreaks, such as COVID-19, or more in 
general in national emergencies or disasters, will also be discussed. The role of telemedicine in the 
context of team-based hypertensive patient management programs will also be addressed, with 
indications for further progress in the field. 
The document has been conceived and developed by a pool of international experts in the field 
and contains practical recommendations for the use of telemedicine tools in hypertension 
management. 
The main concepts and recommendations are summarized in accompanying tables. 
DEFINITIONS AND CLASSIFICATION 
In this section, the current definition of telemedicine and related terms in the context of e-health 
is provided.  
E-health embraces a wide range of multi-directional activities that make use of ICT to store, 
retrieve, share, exchange, and automate responses to health-related information for prevention, 
diagnosis, and treatment, and for monitoring, educational, and administrative purposes [8]. 
Telemedicine (or telehealth) allows the automatic exchange of medical information (e.g., health 
parameters, biological signals, diagnostic images, etc.), between individuals and their healthcare 
providers, in order to provide disease management at a distance [1,9]. A specific application of 
telemedicine is telemonitoring, which comprises remote monitoring of various vital and non-vital 
parameters and management of people usually with long term conditions. Telemedicine is often 
undertaken using mobile phones, known as m-health. A set of common definitions and examples 
for e-health and the different telemedicine services is provided in TABLE S1 (please see 
http://hyper.ahajournals.org). 
Currently,  the most common way to deliver telemedicine services is by the Internet, often using 
mobile devices and using a “closed-loop” healthcare model also called “Internet-of-Medical-
Things” (IoMT), which is schematically outlined in FIGURE 1 and further discussed in the next 
sections of the paper [5]. 
SOLUTIONS 
Telemedicine solutions involve several different tools aimed at the creation of a connected 
infrastructure of health systems and services, between the patient and the caregiver, or among 
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different healthcare professionals. Typical services provided through telemedicine are summarized 
in TABLE S2, many of which intersect to allow comprehensive patient management. 
DEVICES 
Telemedicine requires devices for collecting and exchanging information between remote sites. 
These devices can include a camera for video exchange, a microphone, and speakers for exchanging 
audio information and sensors for collecting specific vital or non-vital parameters. A list of 
potential devices is reported in TABLE S3. 
COMMUNICATION AND TRANSMISSION 
Usually, telemedicine services are provided using specific interfaces such as desktop or laptop 
computers, mobile phones (smartphones), PDAs, or virtual assistants (e.g., Amazon’s Echo Dot or 
Google Home Mini) or tablet devices, that allow the collection and remote transmission of the 
information. Data gathering may occur through embedded tools or external sensors, such as 
cameras, microphones, or medical devices, and utilizing wired or wireless technologies (including 
BlueTooth, wifi, NFC, ZigBee, etc.). Telemedicine services commonly use websites or web portals 
to create interaction between users. However, a basic form of telemedicine is represented by 
telephone communication [10], with the caveat that management of hypertension and major chronic 
conditions in the absence of any physiological monitoring (i.e. based on symptomatology alone) is 
challenging. Text messaging (SMS) or e-mails represent other simple and popular ways of 
communication, while smartphone apps are becoming the norm. 
Commonly, the interaction between patients and caregivers may be immediate (synchronous) or 
periodic (asynchronous). Typical examples of the first type of interaction are those occurring during 
live audio-video conferencing between a healthcare professional and the patient or during real-time 
transmission of vital signs from the patient’s home to an emergency care unit. Examples of 
asynchronous interactions are represented by remote interpretation or telereporting of previously 
transmitted data, e-mail messaging or SMS, smartphone apps, or online programs for education. 
This asynchronous approach can be particularly helpful in managing large numbers of patients as 
messaging confirming normality, where appropriate, can be done quickly on a large scale leaving 
direct synchronous communication largely where parameters are not normal, and management 
needs to be adjusted. 
Some practical examples of telemonitoring tools for hypertension management are summarized 
in TABLE S4. 
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SETTINGS AND POPULATIONS 
SETTINGS 
Current settings where telemedicine services for hypertensive patients are deployed, and their 
characteristics are summarized in TABLE 1. The different settings are interconnected according to 
a modern patient-centered model aiming at providing personalized or precision medicine. In this 
regard, telemedicine can foster a multidisciplinary and team-based approach to hypertension 
management provided that the different services are not siloed either technologically or 
professionally. 
TARGET POPULATIONS 
Telemedicine services may be targeted to two main types of populations.  
Individuals who require screening for possible high blood pressure 
The first and larger population includes all those individuals requiring screening for possible 
hypertension due to a potential risk based on genetic, environmental, or behavioral factors. This 
group would benefit from telemedicine in a general sense, including BP monitoring, along with 
screening for other risk factors (e.g., hypercholesterolemia, aortic aneurysm, bowel cancer 
screening, etc.). 
Treated patients 
The second group of patients includes those taking antihypertensive drug treatment, needing 
surveillance and follow-up. Two categories of patients may be identified. One includes patients at 
high risk of CV complications, suffering from comorbidities, resistant to antihypertensive 
treatment, or showing low adherence to the therapeutic plan. This category of patients needs more 
intensive telemonitoring and tighter surveillance. The second category of patients includes those at 
lower risk or less severe, with controlled BP, who may experience BP rises over time or more acute 
periods of uncontrolled BP and may thus benefit from intermittent telemonitoring. 
IMPLEMENTATION OF TELEMEDICINE SERVICES WORLDWIDE 
Exact estimates of the implementation of telemedicine services among hypertensive patients 
worldwide are lacking. However, recent statistics suggest that around the world seven million 
patients are managed by telemedicine, with the most popular applications targeting patients with 
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heart failure, hypertension and diabetes [5]. Europe and North America dominate the market of 
telemedicine, but emergent markets include Asia and Oceania. Although televisit and 
teleconsultation are the most popular telemedicine solutions, home-based telemonitoring relying on 
m-health apps is the fastest growing application of telemedicine and it is expected to help ongoing 
implementation of telemedicine, particularly in the context of a global pandemic [5]. 
SCIENTIFIC EVIDENCE FROM STUDIES 
FEASIBILITY AND ACCEPTABILITY OF TELEMONITORING 
In general, telemedicine in hypertension is feasible on a wide scale and well-received with 
excellent acceptability. In 13 studies (5 carried out in hospitals, 5 in general practices, 3 in the 
community) including 1,662 patients, the average adherence to telemedicine-based hypertension 
management programs was reasonably high: 76.8% of patients complied with the telemonitoring 
schedule (range 48-90%) [11]. In 10 studies (3 carried out in hospitals, 5 in general practices, and 2 
in the community) enrolling 1,120 patients, 87.1% of the participants regarded the telemedicine 
solution as useful to manage their condition (range 69% - 100%) [11]. 
The recent coronavirus outbreak (COVID-19 pandemic) has shown what happens where patients 
are unable to visit their physicians at healthcare facilities due to fear of infection. Similar issues are 
relevant for people who find attendance at their healthcare provider difficult due to distance, 
disability, lack of transportation, or other commitments. In all of these situations, a telemedicine 
solution provides option for adequate care, and in most cases of hypertension, care requires 
telemonitoring of BP. 
OVERALL PROOF OF EFFICACY 
In this section, we present an umbrella review of the available systematic reviews and meta-
analyses based on randomized controlled studies making use of telemedicine for the management of 
hypertension [12-26]. Given the evolution of ICT in recent years and the improvement in healthcare 
models based on telemedicine, we have focused on reviews published in the last decade, which 
reflect the current solutions available to healthcare professionals and patients. 
The most successful telemedicine approach appears to be the one based on telemonitoring of BP 
and tracking of additional vital and non-vital signs with data exchange between patients and a case 
manager (usually a nurse or a pharmacist under the supervision of a clinician) through the web, e-
mails, text messaging, or video consultation, integrated with education on lifestyle, risk factors and 
proper use of antihypertensive medications. The greatest effect observed is when delivery of the 
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intervention is proactive and not passive and when the intervention is driven by healthcare 
professionals - rather than patient-driven. Following the diffusion of mobile-apps, more direct 
involvement of the patient through self-management, perhaps under the supervision of a 
multidisciplinary clinical team (usually including one or more a healthcare professionals supported 
by a trained non-healthcare professional with technical skills) seems to be promising. More patient 
involvement would allow increasing numbers of patients to be served by a single medical facility. 
TABLE 2, summarizes the quality level, the methodology and the main results of systematic 
reviews and meta-analyses suggesting that randomized controlled studies published to date have 
shown greater BP reductions and a larger proportion of patients achieving BP control when a 
telemedicine approach is utilized compared to usual care. Some trials have compared BP 
telemonitoring with BP self-monitoring alone, suggesting that the telemedicine approach has an 
additional benefit in terms of BP control beyond self BP measurement. 
As already discussed, the sustainability and long-term clinical effectiveness of these 
interventions remain unclear, with few studies looking at longer-term benefits beyond 12 months. 
Some evidence suggests ongoing effects even when interventions are stopped, but the optimal 
schedules for long term care once control is achieved are not established [27,28]. Understanding the 
ideal schedules and doses of the intervention (e.g. BP monitoring every month, or 3 months or 6 
months) for long term care aspect is important to elucidate because arterial hypertension is a 
chronic and life-enduring condition. 
The studies performed so far, however, were based on heterogeneous interventions, 
technologies, and study designs, which makes it difficult to identify the right solution for a given 
patient. The only strong evidence available from many studies is that solutions that are based on 
complex interventions, including not only telemonitoring but also multidisciplinary case 
management, education, and feedback to the patient, are the most effective [5]. Future studies 
should be more focused on this multifaceted multimodal approach and test such solutions in 
specific groups of hypertensive patients, such as those with resistant hypertension, those at high risk 
of developing CV diseases, or those with multiple comorbidities. In these patients, the cost-
effectiveness of telemedicine may be higher, and the proof of effectiveness might favor the 
development of reimbursement models. 
In some of the studies included in the meta-analyses, additional effects of the telemedicine 
intervention were observed and are summarized in TABLE 3. However, the strength of these 
effects is less consistent than BP reduction. 
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EFFECTIVENESS IN SPECIFIC HYPERTENSION SUBGROUPS 
There are currently few studies and meta-analyses that have focused on evaluating the benefit of 
telehealth interventions compared to usual care in specific subgroups of hypertensive patients. 
This evidence is discussed in the following paragraphs, and general recommendations is 
provided in TABLE 4.  
Diabetes 
Although several studies have tested the effectiveness of telemedicine in diabetic patients, with 
conflicting results [29], few studies have evaluated its impact in the presence of hypertension plus 
diabetes. In four randomized controlled studies performed among 734 hypertensive patients with 
comorbid diabetes, the intervention group based on telemonitoring plus nurse or clinician 
management resulted in greater reductions in BP, HbA1c, LDL-cholesterol, and a greater 
proportion of participants achieving their BP goal after 6 to 12 months compared to usual care [30-
34]. Medication adherence was increased in one study and unchanged in another. In one study, 
patients achieving a SBP of <120 mmHg had lower average blood sugars than those with higher 
values. Thus, in patients with diabetes and hypertension, telemedicine has the potential for 
delivering intensified care to improve BP control. 
Ethnicity subgroups 
The effectiveness of telemedicine has also been verified in specific high-risk ethnic subgroups. 
The majority of the studies focused on Black Americans living in medically underserved areas. 
Four well-conducted randomized prospective controlled studies evaluated the impact of a 3 to 12 
months nurse-managed telemedicine intervention among 1,533 African-Americans [35-37]. As 
compared to usual care, the intervention was associated with larger BP reductions and enhanced BP 
control, particularly in participants with higher hypertension stages. In another randomized 
controlled trial including 110 African-Americans with uncontrolled hypertension and lasting only 
one month, the authors found no difference in medication adherence and BP control between the 
usual care group and the intervention group receiving fully automated text messaging support [38]. 
Although the evidence of improved hypertension management with telemedicine is largely limited 
to African-Americans [39], there is one small randomized controlled study performed in 80 
Koreans with concomitant obesity and hypertension which showed improved BP, body weight, 
waist circumference, and HDL-cholesterol after two weeks of a web-based intervention through a 
cellular phone and Internet SMS [40]. Another study without a control group included 359 Korean 
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Americans and showed improved BP levels after 12 months of a behavioral education intervention 
based on BP telemonitoring and bilingual nurse telephone counseling [41]. 
Low- and middle-income settings 
In low- and middle-income countries, rapid globalization is progressively increasing the 
incidence of non-communicable diseases, and in particular of hypertension [42]. Given the lack of 
infrastructure and the need for patients to travel long distances from home to hospitals, telemedicine 
may be particularly beneficial in these settings. However, the current evidence of the effectiveness 
of telemedicine on non-communicable diseases in low- and middle-income countries is poor and 
mainly based on m-health interventions [43,44]. These studies show potential benefit from 
promoting physical activity and healthy diets, whereas results for other outcomes are conflicting 
and not definitive. Only one study including hypertensive patients specifically from clinics in 
Honduras and Mexico showed a benefit on BP control after six weeks of follow-up in 200 
participants [45].  
Pregnancy 
A potential application of telemedicine is hypertension monitoring in pregnancy [46]. Although 
several studies show that m-health solutions may represent an important support for managing 
hypertensive disorders during pregnancy and improve current clinical practice, most of the evidence 
is limited to evaluating the feasibility of recruitment to a potential trial, usability of the proposed 
systems and improvement of maternal satisfaction [47,48]. Currently, no study has been of 
sufficiently large size to demonstrate an improvement in BP control or hypertension management in 
pregnancy, but two large studies are due to report in early 2021 [49].  
Patients with cardiovascular or renal disease 
The various telemedicine-based studies performed so far in hypertensive patients were, in some 
cases, conducted in patients who were also affected by additional CV disease or chronic kidney 
disease (CKD.) However, these studies did not provide any significant evidence to support the 
superiority of telemedicine for BP management in these patients. A recently published meta-
analysis [50] investigated whether the effectiveness of self-monitoring of BP combined with a co-
intervention, including telemonitoring, varied by co-morbidity. Self-monitoring of BP combined 
with intense co-interventions was more effective than low-intensity self-monitoring in patients with 
obesity and possibly stroke, but not in patients with coronary artery disease, diabetes, or CKD. 
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A meta-analysis including three studies with 680 participants with hypertension and stage III 
CKD showed a reduction in SBP in the telemedicine group after 1 to 2 years of follow-up; however, 
such reduction was not different from that observed in the usual care group [26]. 
EFFECTIVENESS IN SPECIFIC SETTINGS 
Although most studies focusing on the efficacy of telemedicine among hypertensive patients 
have been performed in hospitals or outpatient clinics, some of them evaluated the impact of 
services deployed with the support of primary care physicians or pharmacists. These settings are 
particularly interesting because they represent the main approach to hypertension management in 
the community. Thus, they may represent the ideal ground for the dissemination of telemedicine in 
the context of hypertension management. 
Community 
As previously summarized in TABLE 2, many studies based on BP telemonitoring have been 
performed in a community setting. These studies show some evidence of effectiveness, particularly 
in the case of underserved areas and ethnic minorities. Furthermore, there is currently great interest 
in new hybrid solutions for remote management of hypertensive patients, based on devices (so-
called “connected kiosks”) placed in community centers, waiting rooms of outpatients or primary 
care clinics, pharmacy or grocery stores [7]. These devices provide unsupervised measurement of 
BP and other relevant parameters, together with collection of information on the individual’s CV 
risk, lifestyle and physical fitness status. These unmanned solutions provide immediate automated 
feedback to the user with the option of requesting support from a remotely connected healthcare 
professional. At present, only results from feasibility studies are available for these tools, while 
their efficacy has still to be proven [51-54].  
Primary care 
One of the major studies evaluating the impact of telemedicine in hypertension management is 
the TASMINH2 Study. This study included 480 hypertensive patients recruited in 24 general 
practices in the UK. It evaluated whether an intervention consisting of self-monitoring of BP and 
self-titration of antihypertensive drugs, combined with telemonitoring of home BP measurements, 
could lead to substantial reductions of BP over one year of follow-up. This intervention was more 
effective in lowering BP than usual care [55] and also represented a cost-effective use of health care 
resources [56]. In another study, the TASMINH4, the same group assessed the efficacy of self-
monitored BP, with or without telemonitoring, vs. usual care for antihypertensive titration in 142 
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general practices and 1,182 high-risk hypertensive patients with poorly controlled BP [57]. After 12 
months of follow-up, self-monitoring of BP, with or without telemonitoring, was associated with 
lower BP values and lower costs than usual care [58]. Although this study did not find any 
significant difference in the effect of telemonitoring compared to that of self-monitoring after 12 
months, BP in the telemonitoring group dropped more quickly (at six months) than in the self-
monitoring alone group, an effect which is desirable in high-risk patients to further decrease the risk 
of CV events. Furthermore, telemonitoring was cost-effective, even when compared to self-
monitoring alone in linked modeling work [58]. 
Another major randomized controlled trial is the HITS Study, conducted in 20 primary care 
practices in south east Scotland and involving 401 hypertensive patients with uncontrolled day-time 
BP. In this study, the intervention consisted of self BP measurement with transmission of BP 
readings to a secure website for review by the attending physician or nurse, with optional automated 
feedback to the patient by text or e-mail. After six months day-time BP was reduced significantly 
more in the intervention than in the usual care group, but was more expensive [59,60]. 
In Italy, the TELEBPCARE Study assessed whether a home BP telemonitoring intervention with 
case management by the general practitioner could improve BP control [61]. The study involved 12 
general practices and 391 hypertensive patients. After six months of follow-up, ambulatory BP 
control was improved in the intervention group, with less frequent treatment changes, a better 
quality of life, and lower management costs. 
Finally, in a Canadian study recruiting 223 primary care hypertensive patients of 8 different 
practices, after one year of follow-up, ambulatory BP was lower, and more patients achieved the BP 
target in the nurse-led BP telemonitoring group under physician supervision [62]. The intervention 
was also associated with more-physician-driven antihypertensive dose adjustments or changes in 
medications and a trend toward improvement in medication adherence. 
A summary of the effect of the intervention vs. usual care on office and ambulatory BP in the 
five studies is presented in FIGURE S1 [55,57,59,61,62]. 
Pharmacy setting 
Few randomized controlled studies have evaluated the impact of community pharmacists in the 
management of hypertensive patients through telemedicine (so-called “telepharmacy”) [24]. In 
these studies, a physician-pharmacist collaborative intervention based on home BP telemonitoring 
together with patient education on lifestyle, drug therapy, and CV risk factors control was 
associated with an enhanced BP control as a consequence of antihypertensive medication 
intensification and optimization. As shown in FIGURE S2, the magnitude of BP reductions and 
13 
 
proportions of patients at target following a 6 to 12-month pharmacist’s intervention were 
significantly larger than those observed in patients randomized to usual care [28,63-71]. The benefit 
of the pharmacist’s intervention was consistently reduced or even abolished months after its 
withdrawal, highlighting the importance of the sustainability of the intervention in the long-term. 
Interestingly, the few studies that also evaluated the cost-effectiveness of the intervention 
documented that the improved BP control could be achieved at a relatively low cost compared with 
the usual care approach. The management of uncomplicated mild hypertensive patients by 
pharmacists licensed to prescribe or adjust medications, as occurs now in many states in the US, 
may help free up physicians to manage more complex patients and may be a more cost-effective 
way to practice. 
More recently, the TEMPLAR project documented an improved screening of high BP by the 
introduction of 24-hour ABPM with medical telereporting and telecounseling in Italian community 
pharmacies [72]. 
BENEFITS 
The major benefits of telemedicine services for hypertension management are summarized in 
TABLE S5 and discussed below. 
Telemedicine may help to build and maintain an enduring and long-term relationship between 
patients and their healthcare providers. Telemedicine may help empower hypertensive patients, 
influencing their attitudes and behaviors, and promote self-management, with improvement in the 
patient’s medical condition. Digital interventions can help reinforce and individualize the 
physician-patient relationship, and thus improve BP and CV risk control [73]. Technological 
innovation due to telemedicine may bring better professional cooperation, information sharing, 
decision support, and flexibility to the healthcare system. Remote patient monitoring through 
telemedicine allows physicians and health facilities to expand their reach, beyond their own offices, 
and to easily provide services to an increased number of patients, with consistent savings in time 
demands, and with the same content quality of traditional in-person consultations. Where face-to-
face contact is difficult due to fear of infection (e.g., in time of pandemic such as that due to 
COVID-19) or due to isolation (as in the case of natural disasters), disability or geography, then 
telemedicine provides opportunities for care where none would otherwise be possible [2]. In 
particular, telemedicine enhances the monitoring, tracking, and communication of various biometric 
information, enabling greater engagement and partnership of patients in their care, reducing their 
stress. In the case of hypertensive patients, telemedicine services can be used to easily and rapidly 
communicate to the referring doctor the occurrence of acute symptoms or sudden BP rises. Finally, 
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telemedicine services offer hypertensive patients the access to diagnostic procedures that might not 
be available otherwise, without the need to cover long distances (e.g., ambulatory BP monitoring or 
electrocardiogram facilities in community pharmacies linked to telemedical reporting services). 
BARRIERS AND CHALLENGES 
The incomplete evidence on the clinical efficacy and economic benefit of telemedicine provided 
so far by randomized studies, technological barriers, high costs of devices, heterogeneity of 
solutions and technologies, lack of infrastructures and standards, lack of reimbursement, privacy 
and security issues, have all hindered the dissemination of telehealth strategies and their adoption in 
the daily practice of healthcare professionals and patients [5,74] (TABLE S6).  
Currently, several services are available on the market, and none appears to be a benchmark 
solution to be used as a reference to standardize a healthcare model based on telemedicine. Existing 
systems are not interoperable and are rarely integrated into the existing healthcare systems and/or 
electronic health records. 
The development of telehealth programs requires investment in infrastructure, including the 
purchase and maintenance of computer hardware and related software, as well as secure means for 
data transmission, compliant with current privacy regulations. Additional costs are those for 
recruitment and licensing of appropriate professionals for service management and those of 
providing training and support services to staff and users. The costs related to implementation of 
telemedicine services, together with the lack of reimbursement of services and consultations, play a 
critical role in preventing or delaying the development and diffusion of telemedicine solutions. 
Poor informatics skill levels, lack of motivation, and inadequate knowledge of the clinical 
usefulness of telemedicine represent major cultural barriers to the routine use of telemedicine, from 
both doctor’s and patient’s perspectives. The educational level and features of the patients targeted 
for the intervention are also important. Resistance to adopting new models of care affects both 
patients and healthcare workforces. To facilitate the diffusion of telehealth services, efforts should 
be dedicated to their integration into the existing organizational structures and to provide 
institutional support to deliver these services. 
REGULATORY AND LEGAL ISSUES 
Several regulatory and legal issues need to be addressed to ensure the quality of telemedicine 
services in hypertension management. These aspects are briefly summarized in TABLE S7 and 
extensively discussed in the next paragraphs. 
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Telemedicine services are based on hardware and/or software and provide medical diagnosis and 
care: thus, they must be classified as medical devices. This means that telemedicine equipment must 
be developed, validated and certified according to the recommendations and indications of 
regulatory bodies. This is particularly relevant for health apps: they are growing rapidly on the 
market, but the majority of them lack an appropriate test for efficacy and quality and are often 
labeled as wellness or fitness products to circumvent regulation when, indeed, most of them act as 
medical devices [75]. These considerations strongly emphasize the importance of scientific 
validation for health apps content, and the need of demonstrating their usefulness through properly 
designed clinical studies [76-78]. 
At the end of the process of development of a telemedicine solution and before the product is 
placed on the market and used by healthcare providers and patients, the manufacturer must provide 
evidence of clinical validation and submit the product to the authority for certification as a medical 
device. In Europe, according to the new EU Regulation 2017/745, software to be used for medical 
purposes (“diagnosis, prevention, monitoring, prediction, prognosis, treatment or alleviation of 
disease”), is defined as a medical device. As such, it must be validated according to state of the art, 
taking into account the principles of the development life cycle, risk management, validation and 
verification, and post-marketing surveillance [79]. 
In the USA, the FDA regulation states that telemedicine software (or m-apps) meet the 
regulatory definition of the device if "intended for use in the diagnosis of disease or other 
conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, 
or intended to affect the structure or any function of the body of man or other animals, and does not 
achieve its primary intended purposes through chemical action within or on the body of man or 
other animals and is not dependent upon being metabolized for the achievement of any of its 
primary intended purposes" [80]. 
A further aspect of telemedicine that is often underestimated is the need for clear guidelines 
about its application and the need for training, certification, and licensing of operators. This applies 
to doctors, nurses and pharmacists, important groups often handling telemedicine solutions. Indeed, 
healthcare professionals used to work in a traditional face-to-face care setting, may need adequate 
training in order to be effective when providing services with telemedicine. In the USA, the 
American Telemedicine Association offers a telemedicine accreditation program for online, 
synchronous patients consultations, which promotes patient safety, transparency of operations, and 
adherence to all relevant laws and regulations [81]. There are also accreditation programs designed 
for organizations that provide telemedicine services, such as those promoted by the Review 
Accreditation Commission [82]. Since telemedicine crosses the boundaries of individual countries, 
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while physician licenses do not, a major challenge to be faced in the future is whether special 
regulations are needed for doctors to provide telemedicine services (e.g., telemonitoring, televisit or 
teleconsultation) to patients dwelling in another country. In the USA, for instance, 12 states foresee 
a special license allowing the physician to practice across state lines for telemedicine only, while 
six states require the physician to register if he wishes to practice across state lines [83]. In Europe, 
doctors can freely practice across the EU member states. However, language is a major challenge to 
provide telemedicine services to local patients.  
Privacy and security issues are important when data are traveling through the web, and they are 
particularly important due to the increasing use of cloud solutions. In particular, the large 
availability of user-friendly smartphones and m-apps is raising great concerns among doctors and 
patients about lack of transparency regarding the utilization and transfer of data, and how data are 
protected from potential breaches and misuse. 
Since telemedicine involves the collection and sharing of patients’ health information, 
safeguards are needed to be put in place to secure the privacy and safety of these data, to minimize 
the risk of a data breach. Any data transmission through the web must be encrypted to ensure 
security. Servers where data are stored must be protected from intruders with firewalls, antivirus 
software, and anti-ransomware tools. Regular data backups and fast procedures for data restoration, 
or even data mirroring must be ensured. 
Compliance with privacy regulations by telemedicine developers and providers is mandatory to 
guarantee the integrity of users’ health data. In Europe, the General Data Protection Regulation 
(GDPR) 2016/679 harmonizes data privacy law across Europe to protect and empower all European 
citizens' data privacy extending the concept of personal data and liability to all data processors [84]. 
In the USA, the Health Insurance Portability and Accountability Act (HIPAA) ensures similar 
security standards for any medical activity associated with telemedicine [85]. 
TELEMEDICINE IN THE SPOTLIGHT AT THE TIME OF COVID-19 AND NATURAL 
DISASTERS 
During the public health emergency due to COVID-19 telemedicine has thrived and emerged 
worldwide as an indispensable resource to improve surveillance of patients, contain the spread of 
the disease, favor early identification and prompt management of infected people, but particularly to 
ensure continuity of care of vulnerable patients with multiple chronic diseases, including 
hypertension [2,3]. The recent pandemic has strongly promoted the use of remote monitoring and 
televisits, where in-person consulting has been greatly reduced or impossible [86,87]. 
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In the next paragraphs, we present the experience collected in the countries of the experts 
involved in the development of the position paper during the COVID-19 pandemic and during 
similar national emergencies.  
In the UK, during the COVID-19 pandemic, there has been a marked swing towards BP 
telemonitoring in antenatal care, underpinned by rapidly-produced national guidelines, with around 
80% of maternity units adopting a program of BP self-monitoring for pregnant women [88]. In 
Scotland, an integrated telemonitoring system for hypertension implemented in the last few years at 
scale in 75 primary care practices and used by 3200 patients with established hypertension, has seen 
a marked increase in the demand and provision of the services by hypertensive patients locked 
down due to the infectious outbreak [89]. 
In Italy, the national health system struggled to sustain the wave of COVID-19 patients due to a 
shortage of personnel, devices and intensive care unit beds. During the two months of lockdown, 
patients with chronic disease and hypertension, kept at distance by hospitals, general practices and 
outpatient specialist clinics, markedly increased their access to health content on the Internet 
seeking qualified and certified telehealth services able to help manage their condition. A significant 
increment in the use of home telemonitoring solutions based on m-health has been observed during 
the lockdown due to the halting of face-to-face visits (+768% new active users and +840% new data 
exchanged). On the other hand, in the same period, telemedicine and telecounseling services daily 
provided to patients through community pharmacies and general practices showed a dramatic drop 
(-881%), because of the reduced access of patients to these premises for fear of contagion [90]. 
Unfortunately, the use of telemedicine by patients at home was hampered by a limited ICT 
infrastructure. 
In the US, because of COVID-19, governmental policies have been introduced to enable broad 
expansion and rapid implementation of telemedicine [2]. There was a relaxing of federal regulatory 
use of telemedicine including allowing the use of telemedicine across state lines and increased 
reimbursement by Medicare (and many other insurers) for telehealth visits for the first time due to 
COVID-19, with close to in-person rates. The government had also funded telehealth services, 
particularly in underserved clinics [91]. Besides, there was continuing work to adapt programs to 
support individuals during the pandemic [92].  
In Canada, the pandemic has pushed physicians to adopt make-shift solutions to provide care 
[93]. Televisits are now commonplace with the telephone being the primary communication tool. 
However, physicians have soon realized that televisits with no monitoring information, no updated 
lab results and no physical assessment have limited value. Most are dissatisfied with the experience. 
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At this point it is unclear how the patients viewed the experience and whether telemedicine will 
boost after the pandemic. 
Telemedicine and BP telemonitoring have also proved to be effective approaches in natural 
disaster situations. In Japan, at the time of the Great East Japan Earthquake in 2011, the Disaster 
Cardiovascular Prevention system providing cloud-based BP telemonitoring, has been introduced 
into the disaster area to manage patients with “disaster hypertension” [94,95] In the acute phase, 
this telemonitoring system was effective to pick up the “real-time” high-risk patients based on 
daily trends of self-measured BP. Among the patients followed through the system, the doctors 
actually identified treated patients with excessive BP reduction by dehydration, or with sudden and 
significant increment in BP, and could contact them in order to adjust therapy [96]. The 
telemonitoring system reduced the frequency of patients’ visits during the immediate time 
following the disaster, but did not miss the high-risk patients confined at home. In a stable situation 
after the acute phase, this system was effective for proactive BP control [97]. 
FINAL RECOMMENDATIONS 
Many current hypertension guidelines do not contain specific recommendations on the use of 
telemedicine for hypertension management [98-104]. As summarized in TABLE S8, only 
American guidelines clearly recommend the use of telemedicine to confirm the diagnosis of 
hypertension and as an adjunct on top of the standard intervention to improve BP control and 
adherence [6]. 
Undoubtedly, evidence about the usefulness of telemedicine for the management of hypertensive 
patients is far from being definitive or consistent. However, in the last decade, the number of well-
conducted and large studies performed in different subgroups of hypertensives and different settings 
has increased. Additionally, the technology has much improved, allowing a more widespread 
diffusion of telemedicine solutions among healthcare doctors and patients. In this sense, the 
proliferation of m-apps has raised awareness among the general public about the importance of 
telemedicine. However, it has also drawn attention to the danger of uncontrolled connected health. 
TABLE 5 summarizes proposals for possible telemedicine provision models based on the 
evidence provided and discussed in the previous sections and originating from the consensus of the 
international experts involved in the present publication. 
In conclusion, telemedicine represents a useful approach to help deliver effective care to 
hypertensive patients and optimize their management by doctors and other care managers. The 
current evidence supports its use in patients with difficult to treat hypertension or poorly adherent to 
medication management. However, more scientific evidence is needed to demonstrate the 
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effectiveness of telemedicine in other specific subgroups and beyond effective BP-lowering and 
control. Besides this aspect, we must acknowledge that several barriers still limit the 
implementation of telemedicine in the routine clinical management of the hypertensive patient, 
including the fact that telemedicine is considered as an add-on to existing care rather than an 
indispensable tool to be blended in current care delivery. This pool of experts is confident that in 
the future, telemedicine will be more and more embedded in standard delivery care models of 
hypertension with great benefits for patients and their doctors. Eventually, the current COVID-19 
crisis will boost this process.  
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NOVELTY AND SIGNIFICANCE 
What is new? 
 This paper summarizes the evidence for the use of telemedicine for hypertension and 
provides recommendations for its implementation internationally, issues not covered in 
many current hypertension guidelines.  
What is relevant? 
 Large randomized controlled studies in the last decade have shown that the use of 
telemedicine is associated with an improved blood pressure control compared to usual care 
 Complex interventions including blood pressure telemonitoring, multidisciplinary case 
management, education and feedback to the patient are the most effective 
Summary 
 Telemedicine is recommended for the screening of suspected hypertension and the 
management of older adults, medically underserved people, high-risk hypertensive patients, 
and those isolated due to pandemics 
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LEGENDS 
 
Figure 1. Diagram of basic telehealth services and their workflow. EHR: Electronic Health 
Record; NFC: Near Field Communication; PDA: Personal Digital Assistant; IoMT: Internet of 
Medical Things; Mic: Microphone [from 5 by permission]. 
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Table 1. Service settings. AHP: Allied Health Professional. 
 General community setting 
- Interactive kiosks located in waiting rooms, supermarkets, etc. (unattended) 
 Health-related community setting and primary care 
- General practitioners and practice nurses 
- Community pharmacists 
- Homecare services 
 AHP services, interfaces between primary and secondary care services 
 Secondary care 
- Outpatient clinics (specialists) 
- Hospital emergency departments, intensive care units, medical imaging services, maternity services 
 Tertiary care 
- General Hospitals 
- Hypertension centers 
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Table 2. Systematic reviews and meta-analyses of studies documenting the efficacy of telehealth compared to usual care in hypertension management. RCT: 
Randomized Controlled Studies: CKD: Chronic Kidney Disease; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; BP: Blood Pressure; eGFR: 
estimated Glomerular Filtration Rate. 
 
Author 
(year) 
Type of 
intervention 
Type of 
subjects Setting 
No. studies 
(comparisons) 
No. 
subjects 
Publication 
year 
(range) 
Quality of 
the studies 
and/or 
publication 
bias 
Median 
length 
(range) 
of 
follow-
up 
(weeks) 
Outcomes 
assessed Summary of main results 
Omboni 
et al. 
(2011) 
[12] 
BP exchanged 
through landline 
or mobile 
telephone/modem 
transmission or 
Internet + patient 
education + case 
manager 
Hypertensive 
patients 
(1 study in 
obese and 1 
in people 
with diabetes 
only) 
Mainly 
general 
practices or 
community 
clinics 
12 RCTs 4,389 1996-2010 
 12 
acceptable 
 Low 
publication 
bias 
24 
(8-240) 
 BP changes 
 Rate of BP 
control 
 Number of 
antihypertensive 
drugs 
 Office (but not ambulatory) BP 
was reduced significantly more 
in patients randomized to the 
intervention 
 Office BP control (percentage 
of patients at target) was better 
in the telemedicine group 
 The intervention was 
associated with a significantly 
increased use of 
antihypertension medications 
Agarwal 
et al. 
(2011) 
[13] 
BP telemonitoring Hypertensive patients 
Mainly 
community 
and general 
practice 
7 RCTs 1,510 1996-2008 
 No 
publication 
bias 
24 
(8-48)  BP changes 
 Greater SBP reduction was 
observed compared to usual 
care in subjects using 
telemonitoring than in those 
performing self-BP monitoring 
without remote transmission 
and counseling 
Verberk 
et al. 
(2011) 
[14] 
BP exchanged 
through landline 
or mobile 
telephone/modem 
transmission or 
Internet + patient 
education + case 
manager 
Hypertensive 
patients 
Mainly 
general 
practices or 
community 
clinics 
9 RCTs 2,501 1996-2010 
 Low 
publication 
bias 
26 
(8-52)  BP changes 
 Larger office BP reduction in 
the intervention group 
 The difference in the effect 
size of the intervention is larger 
if treatment is not modified 
34 
 
Author 
(year) 
Type of 
intervention 
Type of 
subjects Setting 
No. studies 
(comparisons) 
No. 
subjects 
Publication 
year 
(range) 
Quality of 
the studies 
and/or 
publication 
bias 
Median 
length 
(range) 
of 
follow-
up 
(weeks) 
Outcomes 
assessed Summary of main results 
Omboni 
et al. 
(2013) 
[15] 
BP exchanged 
through landline 
or mobile 
telephone/modem 
transmission or 
the Internet, e-
mail + patient 
education + case 
manager 
Hypertensive 
patients 
(1 study only 
obese, 2 
studies only 
diabetics) 
Mainly 
general 
practices or 
community 
clinics 
23 RCTs 7,037 1996-2011 
 23 
acceptable 
 Low 
publication 
bias 
(except for 
cost 
analysis) 
24 
(8-240) 
 BP changes 
 Rate of BP 
control 
 Number of 
antihypertensive 
drugs 
 Adherence to 
treatment 
 Number of 
office visits 
 Healthcare 
costs 
 Quality of life 
 Adverse events 
 Significantly improved office 
BP changes and control with 
the intervention 
 Larger prescription of 
antihypertension medications 
in the intervention group 
 No difference in adherence to 
treatment and number of office 
consultations 
 Intervention is cost-effective if 
only medical costs are 
considered (excluding the 
costs for the technology) 
 Improved physical component 
of quality of life 
 No difference in the risk of 
adverse events 
Zullig et 
al. 
(2013) 
[16] 
Home BP 
monitoring and 
nurse telephone 
call + behavioral 
modification and 
medication 
management 
Hypertensive 
patients 
(stroke or 
TIA) 
Community 
or Hospital 7 RCTs 2,081 2009-2013 
 Very poor 
(only 
descriptive 
review and 
few 
studies 
included) 
12 
(6-24) 
 BP changes 
 Rate of BP 
control 
 Adherence to 
treatment 
 Larger BP reduction in the 
intervention group in 2 studies, 
no effect in 3 studies 
 Improved BP control with the 
intervention (2 studies) 
 More medication changes in 
the intervention group (1 study) 
 No difference in medication 
adherence (1 study) 
Liu et 
al. 
(2013) 
[17]  
Internet-based 
lifestyle 
interventions and 
BP measurement 
during a face-to-
face visit 
Mainly 
hypertensive 
patients (plus 
obese, 
diabetics and 
post-
menopausal 
women) 
Mainly 
community 
and general 
practice 
11 RCTs 
2 not RCTs 
2,221 2004-2012 
 No 
publication 
bias for 
SBP 
 Low 
publication 
bias for 
DBP 
14 
(8-48)  BP changes 
 Internet-based lifestyle 
intervention significantly 
reduced BP 
 The greatest SBP reduction 
was observed for interventions 
that lasted at least 6 months, 
used 5 or more behavior 
change techniques or 
delivered health messaged 
proactively 
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Author 
(year) 
Type of 
intervention 
Type of 
subjects Setting 
No. studies 
(comparisons) 
No. 
subjects 
Publication 
year 
(range) 
Quality of 
the studies 
and/or 
publication 
bias 
Median 
length 
(range) 
of 
follow-
up 
(weeks) 
Outcomes 
assessed Summary of main results 
Niznik 
et al. 
(2017) 
[18] 
Pharmacist-led 
telephonic clinics, 
pharmacist 
management of 
BP through web-
communication, 
electronic 
messaging (e-
mail) or 
telemonitoring + 
education 
Hypertensive 
patients 
(±CKD) 
Pharmacies 7 RCTs 3,336 2008-2014  Not evaluated 
48 
(24-72) 
 BP changes 
 Rate of BP 
control 
 Morbidity and 
mortality 
 
 Significant decrease in BP with 
pharmacist intervention 
compared to usual care 
 Larger proportion of patients 
with controlled BP in the 
intervention group 
 No differences in deaths, 
hospitalizations, number of 
days spent in the hospital, 
Emergency Department visits 
or Skilled Nursing Facility 
admissions 
Tucker 
et al. 
(2017) 
[19] 
Web or phone 
feedback plus 
education, 
counseling or 
telecounseling 
Hypertensive 
patients 
Primary 
care, 
outpatients 
and 
community 
18 RCTs 9,175 2007-2014  Low risk of bias 
48 
(4-72) 
 BP changes 
 Rate of BP 
control 
 Self-monitoring of BP with 
counseling or tele counseling 
or with web/phone feedback 
plus education is associated 
with a significantly larger BP 
reduction and a higher 
proportion of patients at a 
target than usual care 
 Results are consistent at both 
6 and 12 months 
 Trend to attenuation of the 
effect for patients followed up 
for longer than 1 year 
 The effect is more consistent in 
people on fewer BP medication 
and with higher baseline BP 
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Author 
(year) 
Type of 
intervention 
Type of 
subjects Setting 
No. studies 
(comparisons) 
No. 
subjects 
Publication 
year 
(range) 
Quality of 
the studies 
and/or 
publication 
bias 
Median 
length 
(range) 
of 
follow-
up 
(weeks) 
Outcomes 
assessed Summary of main results 
Xiong 
et al. 
(2018) 
[20] 
m-Health 
interventions 
(apps, SMS, voice 
calls or e-mails 
used as reminders 
and/or health 
education and/or 
lifestyle-related 
recommendations, 
digital medicines, 
wireless BP 
monitoring, and 
electronic 
medication tray) 
Hypertensive 
patients  
16 RCTs 
1 non-RCT 
4 before-and-
after studies 
without a 
control group 
 2000-2017 
 6 good 
 7 fair 
 8 poor 
12 
(4-48) 
 Medication 
adherence 
 
 12 out of the 21 studies found 
improvements in the patients’ 
medication adherence 
 
Choi et 
al. 
(2019) 
[21] 
Data transmitted 
by telephone, the 
Internet, mobile 
phones or e-mail 
Hypertensive 
patients Urban 27 RCTs 9,435 1996-2017 
 Low risk of 
bias 
24 
(8-52) 
 BP changes 
 Rate of BP 
control 
 Office (but not ambulatory) BP 
was reduced significantly more 
in patients randomized to the 
intervention 
 Office BP control (percentage 
of patients at target) was better 
in the telemedicine group 
 The intervention was more 
effective in smaller cities 
compared to larger cities 
 The intervention was similar 
regardless of the medically 
underserved areas 
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Author 
(year) 
Type of 
intervention 
Type of 
subjects Setting 
No. studies 
(comparisons) 
No. 
subjects 
Publication 
year 
(range) 
Quality of 
the studies 
and/or 
publication 
bias 
Median 
length 
(range) 
of 
follow-
up 
(weeks) 
Outcomes 
assessed Summary of main results 
Ma et 
al. 
(2019) 
[22] 
e-Health 
interventions 
(interactive 
wireless 
communication by 
smartphone, 
computer, and 
personal digital 
assistance tools, 
self-care 
behavioral change 
or education 
dissemination) 
Hypertensive 
patients 
Mainly 
community 
and general 
practice 
14 RCTs 3,998 2008-2017 
 14 good 
 Low risk of 
bias 
24 
(12-96) 
 Physical 
outcomes (BP, 
body weight, 
cholesterol) 
 Self-care 
behavioral 
outcomes 
(medication 
adherence, 
sodium intake, 
healthy diet, 
physical activity, 
smoking, 
alcohol 
consumption) 
 Psychosocial 
well-being 
(anxiety, stress, 
depression, 
quality of life) 
 The intervention significantly 
reduced office BP and 
significantly decreased the 
proportion of patients with 
inadequate BP control and 
their body weight 
 The sodium intake was 
reduced significantly more in 
patients randomized to the 
intervention 
 The effectiveness of the 
intervention on self-care 
behavioral change and 
psychosocial wellbeing is 
insufficient 
Lu et al. 
(2019) 
[23] 
m-Health 
interventions 
(mobile phones or 
wearable sensors) 
transmitting data 
to care providers 
Hypertensive 
patients 
Mainly 
community 
and general 
practice 
11 RCTs 4,271 2007-2019 
 4 high 
 7 low 
 Low 
publication 
bias 
48 
(4-72)  BP changes 
 The intervention was 
associated with a significantly 
larger BP reduction 
 No significant differences in BP 
reduction were observed 
between trials of shorter and 
longer duration 
 Trials with more frequent 
weekly BP measurement 
weekly had a larger effect on 
DBP than those with less 
frequent measurements 
 The magnitude of BP reduction 
was larger among subjects 
with inadequate baseline BP 
control than among those with 
adequate baseline BP control 
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Author 
(year) 
Type of 
intervention 
Type of 
subjects Setting 
No. studies 
(comparisons) 
No. 
subjects 
Publication 
year 
(range) 
Quality of 
the studies 
and/or 
publication 
bias 
Median 
length 
(range) 
of 
follow-
up 
(weeks) 
Outcomes 
assessed Summary of main results 
Omboni 
et al. 
(2019) 
[24] 
BP exchanged 
through mobile 
phone, telephone, 
modem, Internet 
or e-mail + patient 
education + 
pharmacist 
management 
Hypertensive 
patients 
Community 
pharmacies 4 RCTs 1,565 2008-2018 
 Not 
evaluated 
96 
(24-
216) 
 BP changes 
 Rate of BP 
control 
 Cost-
effectiveness 
 BP reductions and proportions 
of patients at target following a 
pharmacist’ intervention were 
significantly larger than those 
in the usual care group 
 The benefit of the pharmacist’s 
intervention was markedly 
reduced or abolished months 
after its withdrawal 
 Improved BP control was 
achieved at a relatively low 
cost compared with the usual 
care (3 studies) 
Alessa 
et al. 
(2019) 
[25] 
m-Health 
interventions 
(smartphone app, 
+ e-mail, SMS, 
voice calls used 
as contact and/or 
health education 
and/or lifestyle-
related 
recommendations, 
electronic 
medication 
device, wireless 
BP monitoring) 
Patients with 
hypertension, 
metabolic 
syndrome, 
obstructive 
sleep apnea, 
and obesity 
Primary 
care or 
community 
clinics, 
outpatient 
clinics, 
Hospitals 
9 RCTs 
5 non-
randomized 
studies 
2,402 2012-2017 
 2 good 
 4 fair 
 8 poor 
24 
(8-52)  BP changes 
 The majority (10 / 14) of 
studies demonstrated a 
positive effect on SBP, 
whereas the others showed a 
neutral effect 
 Apps that are incorporating 
more comprehensive 
functionalities are likely to be 
more effective 
Luo et 
al. 
(2019) 
[26] 
BP telemonitoring 
+ telephone 
follow-up or 
interactive video 
consultation + 
education 
program 
Patients with 
hypertension 
and CKD 
stage III 
Community 
and 
outpatient 
clinics 
3 RCTs 680 2011-2014 
 3 
moderate 
quality 
 3 low risk 
of bias 
24 
(24-48) 
 BP changes 
 Creatinine 
changes 
 eGFR changes 
 SBP was reduced by the 
intervention and DBP 
increased, with no statistically 
significant difference compared 
to usual care 
 BP control rates were not 
significantly improved 
 Serum creatinine was non-
significantly decreased, and 
eGFR was maintained at 
baseline levels 
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Table 3. Summary of the evidence for benefits of telemedicine in hypertension management compared to 
usual care. 
Type of outcome Effect Strength of evidence 
 BP reduction Increased Moderate 
 BP control Improved High 
 Use of antihypertensive medications Increased Low 
 Adherence to antihypertensive treatment Improved Very low 
 Frequency of office consultations Reduced Low 
 Quality of life or psychosocial wellbeing Improved Low 
 Drug safety Improved Very low 
 Costs Reduced Very low 
 Deaths and/or hospitalization Reduced Very low 
 
 
Table 4. Effectiveness of telemedicine on different subgroups of hypertensive patients. CKD: Chronic 
Kidney Disease. 
Significant effects Non-significant effects or insufficient evidence 
 Patients with higher BP  Patients with coronary artery disease 
 Obese patients  Patients with CKD 
 Patients with previous stroke  Patients in developing countries 
 Diabetic patients  Pregnant women 
 African-Americans 
(living in medically underserved areas) 
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Table 5. Recommendations for hypertension management with telemedicine: proposed healthcare 
models. BP: Blood Pressure; COVID: COrona VIrus Disease. 
 Type of service 
- Remote monitoring of vital signs (e.g., BP) + medication adherence + education on lifestyle and 
risk factors + asynchronous feedback (best option) 
- Combined with telephone or video consultation (optional) 
 Type of case management and feedback 
- Automatic responses based on interpretative algorithms 
- Attended services (non-medical case manager, physician, nurse or pharmacist) 
- Mixed automatic services with multidisciplinary clinical team supervision (ideal option) 
 Type of medical intervention 
- Structured care 
- Integrated multilevel management by different healthcare professionals (nurse or pharmacist) (best 
option) 
 Target populations: 
- Screening for suspected hypertension (or white-coat hypertension) 
- Ongoing management of hypertension, especially: 
- Older adults 
- Medically underserved populations (deprived areas) 
- High-risk hypertensive patients (resistant hypertensives, patients with poor medication 
adherence) 
- Multimorbidity (diabetes, obesity, stroke) 
- Where face to face consultation is difficult due to geography or pandemic or other national 
emergencies and consequent lockdown (e.g., COVID-19) 
 
